Wedbush Securities Inc. has a $1.26M stock position in Zoetis Inc. (NYSE:ZTS)

Wedbush Securities Inc. reduced its holdings in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 15.0% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,282 shares of the company’s stock after selling 1,287 shares during the quarter. Holdings held by Wedbush Securities Inc. holdings in Zoetis were worth $1,262,000 at the end of the most recent reporting period.

Several other hedge funds have recently modified their positions in ZTS. Webster Bank NA raised its stake in shares of Zoetis by 89.1% in the first quarter. Webster Bank NA now owns 174 shares of the company’s stock worth $29,000 after acquiring an additional 82 shares in the last quarter. Private Wealth Management Group LLC bought a new position in shares of Zoetis in the 4th quarter valued at approximately $33,000. Neo Ivy Capital Management bought a new position in shares of Zoetis in the 4th quarter valued at about $40,000. LRI Investments LLC bought a new position in shares of Zoetis in the first quarter worth about $43,000. Finally, Blue Bell Private Wealth Management LLC raised its stake in shares of Zoetis by 111.6% in the first quarter. Blue Bell Private Wealth Management LLC now owns 273 shares of the company’s stock worth $46,000 after acquiring an additional 144 shares during the last quarter. 92.80% of shares are owned by institutional investors.

Zoetis trading down 0.2%

Shares of ZTS stock opened at $191.37 on Wednesday. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45, and a quick ratio of 2.09. The company has a fifty day moving average price of $181.93 and a two hundred day moving average price of $174.31. Zoetis Inc. it has a one year low of $144.80 and a one year high of $201.92. The stock has a market cap of $86.70 billion, a price-to-earnings ratio of 36.87, a price-to-earnings-growth ratio of 2.90 and a beta of 0.88.

Zoetis (NYSE:ZTS – Get Your Free Report ) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. In the same period last year, the business posted earnings per share of $1.41. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. Equities analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current year.

Analysts on Wall Street are forecasting an increase

Several brokerages have recently weighed in on ZTS. Stifel Nicolaus reaffirmed a “buy” rating and set a $200.00 target price on shares of Zoetis in a research note on Tuesday, August 27th. BTIG Research upped their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Finally, Piper Sandler boosted their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Zoetis currently has a consensus rating of “Buy” and a consensus price target of $217.11, according to MarketBeat .

Check out our latest research report on Zoetis

Zoetis Company Profile

(Free Report)

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products and services in the United States and internationally. The company mainly markets products by species, including livestock such as cattle, swine, poultry, fish and sheep and others; and pets including dogs, cats and horses.

See Also

Want to see what other hedge funds own ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Zoetis Inc. (NYSE:ZTS – Free Report).

Get news and reviews for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.